Fasching PA, Beck JT, Chan A, et al. - Given that significantly improved progression-free survival (PFS) and overall survival (OS) in relation to treatment with ribociclib plus fulvestrant have been reported in the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, researchers herein analyzed patient-reported outcomes from the trial, including health-related quality of life (HRQOL). Patients were randomly assigned (2:1) to receive ribociclib plus fulvestrant or placebo plus fulvestrant. Findings showed that adding ribociclib to fulvestrant not only maintained HRQOL but also afforded significantly prolonged PFS and OS vs placebo plus fulvestrant.